ResMed (RMD) PT Raised to $267 at Needham & Company on Philips Recall Opportunity
Tweet Send to a Friend
Needham & Company analyst Michael Matson raised the price target on ResMed (NYSE: RMD) to $267.00 (from $229.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
